Answers are grounded in this paper and cite their sources.
Brief Reports1 January 1988Metoprolol-lnduced Hepatitis: Rechallenge and Drug Oxidation PhenotypingDOMINIQUE LARREY, M.D., JEAN HENRION, M.D., FRANCIS HELLER, M.D., GERARD BABANY, M.D., CLAUDE DEGOTT, M.D., DOMINIQUE PESSAYRE, M.D., JEAN-PIERRE BENHAMOU, M.D.DOMINIQUE LARREY, M.D., JEAN HENRION, M.D., FRANCIS HELLER, M.D., GERARD BABANY, M.D., CLAUDE DEGOTT, M.D., DOMINIQUE PESSAYRE, M.D., JEAN-PIERRE BENHAMOU, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-1-67 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMetoprolol is a widely used beta-adrenoreceptor antagonist. To our knowledge, there is no report of hepatitis involving this drug as well as other beta-adrenoreceptor antagonists (1). Metoprolol is metabolized by three major oxidation pathways (2); two of them, O-dealkylation and alpha-hydroxylation, undergo genetically controlled polymorphisms correlated with that of debrisoquine oxidation (2-4). This finding strongly suggests that metoprolol oxidation depends at least partly on the same isozyme of cytochrome P-450 involved in the genetic polymorphism of oxidation of debrisoquine and many other drugs such as sparteine, perhexiline, and several other beta-adrenoreceptor antagonists (5). Poor metabolizers of debrisoquine and metoprolol exhibit...References1. STRICKER B and SPOELSTRA P. Drug-Induced Hepatic Injury: A Comprehensive Survey of the Literature on Adverse Drug Reactions up to January 1985. Amsterdam: Elsevier; 1985: 96-7. Google Scholar2. SILAS J, MCGOURTY J, LENNARD M, TUCKER G, and WOODS H. Polymorphic metabolism of metoprolol: clinical studies. Eur J Clin Pharmacol. 1985;28 (suppl):85-8. CrossrefMedlineGoogle Scholar3. LENNARD M, SILAS J, FREESTONE S, RAMSAY L, TUCKER G, and WOODS H. Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-60. CrossrefMedlineGoogle Scholar4. MCGOURTY J, SILAS J, LENNARD M, TUCKER G, and WOODS H. Metoprolol metabolism and debrisoquine oxidation polymorphism—population and family studies. Br J Clin Pharmacol. 1985;20:555-66. CrossrefMedlineGoogle Scholar5. JACQZ E, HALL S, and BRANCH R. Genetically determined polymorphisms in drug oxidation. Hepatology. 1986;6:1020-32. CrossrefMedlineGoogle Scholar6. MORGAN M, RESHEF R, SHAH R, OATES N, SMITH R, and SHERLOCK S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984;25:1057-64. CrossrefMedlineGoogle Scholar7. EVANS D, MAHGOUB A, SLOAN T, IDLE J, and SMITH R. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-5. CrossrefMedlineGoogle Scholar8. SHEAR N, SPIELBERG S, GRANT D, TANG B, and KALOW W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-84. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DOMINIQUE LARREY, M.D.; JEAN HENRION, M.D.; FRANCIS HELLER, M.D.; GERARD BABANY, M.D.; CLAUDE DEGOTT, M.D.; DOMINIQUE PESSAYRE, M.D.; JEAN-PIERRE BENHAMOU, M.D.Affiliations: Hôpital Beaujon Clichy France Hôpital de Jolimont Haine Saint-Paul Belgium PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAcute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinibIdentification of Metoprolol Tartrate-Derived Reactive Metabolites Possibly Correlated with Its Cytotoxicityβ-Blocker-Induced Liver Injury: A Class Effect With Incidental RechallengeDrug-Induced Liver InjuryDrug-Induced Liver InjuryLevetiracetam-induced transaminitis in a young male with traumatic brain injuryDrug-induced HepatotoxicityMetoprololHepatotoxicity of Cardiovascular and Antidiabetic DrugsDrug-Induced Liver InjuryDrug‐Induced Liver DiseaseDrug-Induced Liver InjuryLiver Disease Caused by DrugsFatal subacute liver failure after repeated administration of sevoflurane anaesthesiaCiprofloxacin-Induced Hepatotoxicity Resolved with Levofloxacin: A Case Report and a Review of the LiteratureAtenolol Hepatotoxicity: Report of a Complicated CaseClopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the LiteratureDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisMetoprololDrug-Induced Liver InjuryMetoprolol 37350-58-6Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case reportAcute Cholestatic Hepatitis Associated With PravastatinGENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASEHepatotoxityHypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated HepatitisClinical consequences of polymorphic drug oxidationLabetalol HepatotoxicityJohn A. Clark, MD, MSPH, Hyman J. Zimmerman, MD, Lelia Ann Tanner, RPhFatal labetalol-induced hepatic injuryDrug-induced Liver DiseaseGenetically determined oxidation polymorphism and drug hepatotoxicityβ-Adrenoceptor antagonists and antianginal drugs 1 January 1988Volume 108, Issue 1Page: 67-68KeywordsDrugsGenetic polymorphismHepatitis AHepatitis B ePublished: 1 December 2008 Issue Published: 1 January 1988 PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Dominique Larrey (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: